We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
+20.92%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$2.42B
AUM Growth
+$350M
Cap. Flow
+$135M
Cap. Flow %
5.56%
Top 10 Hldgs %
42.31%
Holding
83
New
4
Increased
11
Reduced
18
Closed
3

Top Buys

Rank Stock Value
1
IONS icon
Ionis Pharmaceuticals
IONS
+$67.3M
2
THRD
Third Harmonic Bio
THRD
+$63.1M
3
RVMD icon
Revolution Medicines
RVMD
+$22M
4
ALLK
Allakos
ALLK
+$21M
5
VERV
Verve Therapeutics
VERV
+$20.7M

Top Sells

Rank Stock Value
1
RCUS icon
Arcus Biosciences
RCUS
+$32.9M
2
XENE icon
Xenon Pharmaceuticals
XENE
+$25.1M
3
EQRX
EQRx, Inc. Common Stock
EQRX
+$23.4M
4
MRUS
Merus
MRUS
+$15.2M
5
SNDX icon
Syndax Pharmaceuticals
SNDX
+$12.5M

Sector Composition

Rank Sector Weight
1 Healthcare 98.88%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CALT
51
DELISTED
Calliditas Therapeutics AB American Depositary Shares
CALT
$11.3M 0.47%
750,000
– –
CTMX icon
52
CytomX Therapeutics
CTMX
$684M
$9.56M 0.4%
6,595,801
+792,101
+14% +$1.22M
IMA
53
ImageneBio Inc
IMA
$62.9M
$8.89M 0.37%
208,589
– –
ALPN
54
DELISTED
Alpine Immune Sciences Inc
ALPN
$8.18M 0.34%
1,135,940
-139,300
-11% -$1.15M
INFI
55
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$7.56M 0.31%
6,353,645
– –
HLVX
56
DELISTED
HilleVax
HLVX
$6.54M 0.27%
382,452
-61
-0% -$887
ELDN icon
57
Eledon Pharmaceuticals
ELDN
$259M
$6.42M 0.27%
2,326,710
– –
PVLA
58
Palvella Therapeutics
PVLA
$2.02B
$5.84M 0.24%
63,504
– –
PYXS icon
59
Pyxis Oncology
PYXS
$167M
$5.79M 0.24%
2,938,851
– –
CBIO
60
Crescent Biopharma
CBIO
$519M
$5.27M 0.22%
95,443
– –
CDTX
61
DELISTED
Cidara Therapeutics
CDTX
$4.31M 0.18%
343,056
– –
SPRO icon
62
Spero Therapeutics
SPRO
$68.3M
$3.86M 0.16%
1,929,376
-1,160,239
-38% -$1.15M
MTEM
63
DELISTED
Molecular Templates, Inc.
MTEM
$3.75M 0.15%
333,104
– –
MOLN
64
Molecular Partners
MOLN
$2.97M 0.12%
443,221
– –
IVA
65
Inventiva
IVA
$1.04B
$2.65M 0.11%
686,040
– –
ELEV
66
DELISTED
Elevation Oncology
ELEV
$2.61M 0.11%
2,312,200
– –
RNAC icon
67
Cartesian Therapeutics
RNAC
$219M
$2.28M 0.09%
46,392
-11,046
-19% -$607K
GBIO
68
DELISTED
Generation Bio
GBIO
$1.92M 0.08%
36,182
-119,421
-77% -$7.47M
FWP
69
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$1.52M 0.06%
513,791
– –
XFOR icon
70
X4 Pharmaceuticals
XFOR
$374M
$1.45M 0.06%
28,263
– –
CALA
71
DELISTED
Calithera Biosciences, Inc
CALA
$1.37M 0.06%
464,742
– –
LITS
72
Lite Strategy Inc
LITS
$32.7M
$1.36M 0.06%
176,603
– –
CRVS icon
73
Corvus Pharmaceuticals
CRVS
$1.1B
$1.12M 0.05%
1,370,947
– –
RNTX
74
Rein Therapeutics
RNTX
$63.6M
$1.09M 0.04%
263,278
– –
ELTX icon
75
Elicio Therapeutics
ELTX
$73.8M
$986K 0.04%
107,130
– –
1 2
3
4

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q3 2022 Portfolio in Review

As of Q3 2022, BVF Inc held 83 positions worth $2.42B, up 17% from $2.07B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

BVF Inc deployed $135M of net new capital in Q3 2022, opening 4 new positions and adding to 11 existing holdings. Its largest new stake was Third Harmonic Bio: 3,501,814 shares worth $66.4M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier.

On the sell side, the largest reduction was Arcus Biosciences, an estimated $32.9M trimmed.

  • BVF Inc's largest Q3 2022 buy was Third Harmonic Bio: 3,501,814 shares worth $66.4M.
  • BVF Inc added most to Ionis Pharmaceuticals in Q3 2022, an estimated $67.3M increase.
  • BVF Inc's biggest Q3 2022 reduction was Arcus Biosciences, cutting an estimated $32.9M.
  • BVF Inc fully exited Protagonist Therapeutics in Q3 2022, selling an estimated $8.76M.
  • BVF Inc's ten largest holdings make up 42% of its $2.42B portfolio in Q3 2022.
  • BVF Inc opened 4 new positions and closed 3 in Q3 2022.
  • BVF Inc's portfolio value rose 17% quarter-over-quarter to $2.42B.

Based on BVF Inc's 13F filing for Q3 2022, filed 14 Nov 2022.